Header Logo

Connection

PAVAN REDDY to Humans

Back to Details
This is a "connection" page, showing publications PAVAN REDDY has written about Humans.
PAVAN REDDY
Connection Strength
0.784
Humans
  1. Inflammatory memory of stem cells: implications for hematologic diseases. Blood. 2025 Sep 11; 146(11):1265-1275.
    View in: PubMed
    Score: 0.026
  2. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. Blood. 2024 01 04; 143(1):21-31.
    View in: PubMed
    Score: 0.023
  3. Bringing CAR T?cell therapy trials to underserved populations. Cancer Cell. 2023 12 11; 41(12):2007-2010.
    View in: PubMed
    Score: 0.023
  4. Feasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantation. Nat Med. 2023 Nov; 29(11):2805-2813.
    View in: PubMed
    Score: 0.023
  5. LNCing RNA to immunity. Trends Immunol. 2022 06; 43(6):478-495.
    View in: PubMed
    Score: 0.020
  6. Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. Blood Adv. 2021 12 14; 5(23):5047-5056.
    View in: PubMed
    Score: 0.020
  7. Mitochondrial complex II in intestinal epithelial cells regulates T cell-mediated immunopathology. Nat Immunol. 2021 11; 22(11):1440-1451.
    View in: PubMed
    Score: 0.020
  8. RNA-seq of human T cells after hematopoietic stem cell transplantation identifies Linc00402 as a regulator of T cell alloimmunity. Sci Transl Med. 2021 03 17; 13(585).
    View in: PubMed
    Score: 0.019
  9. ER-to-Golgi transport and SEC23-dependent COPII vesicles regulate T cell alloimmunity. J Clin Invest. 2021 01 19; 131(2).
    View in: PubMed
    Score: 0.019
  10. ATG5-Dependent Autophagy Uncouples T-cell Proliferative and Effector Functions and Separates Graft-versus-Host Disease from Graft-versus-Leukemia. Cancer Res. 2021 02 15; 81(4):1063-1075.
    View in: PubMed
    Score: 0.019
  11. In response to "American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults". Blood Adv. 2020 11 10; 4(21):5431-5432.
    View in: PubMed
    Score: 0.019
  12. Short chain fatty acids: Postbiotics/metabolites and graft versus host disease colitis. Semin Hematol. 2020 01; 57(1):1-6.
    View in: PubMed
    Score: 0.018
  13. Targeting Signal 3 Extracellularly and Intracellularly in Graft-Versus-Host Disease. Front Immunol. 2020; 11:722.
    View in: PubMed
    Score: 0.018
  14. Host NLRP6 exacerbates graft-versus-host disease independent of gut microbial composition. Nat Microbiol. 2019 05; 4(5):800-812.
    View in: PubMed
    Score: 0.016
  15. Editorial: Non-coding RNAs and Graft versus Host Disease. Front Immunol. 2018; 9:2713.
    View in: PubMed
    Score: 0.016
  16. Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation. J Immunol. 2018 12 01; 201(11):3443-3455.
    View in: PubMed
    Score: 0.016
  17. Non-Coding RNA Mediated Regulation of Allogeneic T Cell Responses After Hematopoietic Transplantation. Front Immunol. 2018; 9:1110.
    View in: PubMed
    Score: 0.016
  18. a1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. Blood. 2018 03 22; 131(12):1372-1379.
    View in: PubMed
    Score: 0.015
  19. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. Blood. 2017 10 12; 130(15):1760-1767.
    View in: PubMed
    Score: 0.015
  20. Regulating Damage from Sterile Inflammation: A Tale of Two Tolerances. Trends Immunol. 2017 04; 38(4):231-235.
    View in: PubMed
    Score: 0.014
  21. Tissue tolerance: a distinct concept to control acute GVHD severity. Blood. 2017 03 30; 129(13):1747-1752.
    View in: PubMed
    Score: 0.014
  22. SAG/Rbx2-Dependent Neddylation Regulates T-Cell Responses. Am J Pathol. 2016 10; 186(10):2679-91.
    View in: PubMed
    Score: 0.014
  23. Advances in understanding the pathogenesis of graft-versus-host disease. Br J Haematol. 2016 Apr; 173(2):190-205.
    View in: PubMed
    Score: 0.013
  24. Selected Reviews from the 2016 BMT Tandem Meetings. Biol Blood Marrow Transplant. 2016 Mar; 22(3 Suppl):S1-2.
    View in: PubMed
    Score: 0.013
  25. Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans. Blood. 2015 Jan 29; 125(5):815-9.
    View in: PubMed
    Score: 0.012
  26. Current and emerging strategies for the prevention of graft-versus-host disease. Nat Rev Clin Oncol. 2014 Sep; 11(9):536-47.
    View in: PubMed
    Score: 0.012
  27. The difficulty in diagnosing cord colitis. Biol Blood Marrow Transplant. 2014 Jul; 20(7):906-7.
    View in: PubMed
    Score: 0.012
  28. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014 Jan; 15(1):87-95.
    View in: PubMed
    Score: 0.011
  29. Neddylation plays an important role in the regulation of murine and human dendritic cell function. Blood. 2013 Sep 19; 122(12):2062-73.
    View in: PubMed
    Score: 0.011
  30. Mouse models in bone marrow transplantation and adoptive cellular therapy. Semin Hematol. 2013 Apr; 50(2):131-44.
    View in: PubMed
    Score: 0.011
  31. Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease. J Leukoc Biol. 2012 Apr; 91(4):667-75.
    View in: PubMed
    Score: 0.010
  32. GVHD prevention: an ounce is better than a pound. Biol Blood Marrow Transplant. 2012 Jan; 18(1 Suppl):S17-26.
    View in: PubMed
    Score: 0.010
  33. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci U S A. 2012 Jan 10; 109(2):564-9.
    View in: PubMed
    Score: 0.010
  34. Impact of pre-existing hepatitis B infection on the outcomes of kidney transplant recipients in the United States. Clin J Am Soc Nephrol. 2011 Jun; 6(6):1481-7.
    View in: PubMed
    Score: 0.010
  35. HDAC inhibition and graft versus host disease. Mol Med. 2011 May-Jun; 17(5-6):404-16.
    View in: PubMed
    Score: 0.009
  36. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest. 2008 Jul; 118(7):2562-73.
    View in: PubMed
    Score: 0.008
  37. GVHD pathophysiology: is acute different from chronic? Best Pract Res Clin Haematol. 2008 Jun; 21(2):101-17.
    View in: PubMed
    Score: 0.008
  38. Biological advances in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation. 2008 Feb 15; 85(3):303-8.
    View in: PubMed
    Score: 0.008
  39. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res. 2007 Oct; 150(4):197-214.
    View in: PubMed
    Score: 0.007
  40. Extracorporeal photo-chemotherapy for graft-versus-host disease. Haematologica. 2005 Aug; 90(8):1013B.
    View in: PubMed
    Score: 0.006
  41. Oral inflammation and microbiome dysbiosis exacerbate chronic graft-versus-host disease. Blood. 2025 Feb 20; 145(8):881-896.
    View in: PubMed
    Score: 0.006
  42. Interleukin-18: recent advances. Curr Opin Hematol. 2004 Nov; 11(6):405-10.
    View in: PubMed
    Score: 0.006
  43. Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease. Cell Host Microbe. 2024 Sep 11; 32(9):1621-1636.e6.
    View in: PubMed
    Score: 0.006
  44. Recruitment and Retention of Hematopoietic Cell Transplantation and Cellular Therapy Physicians: A Report from the ASTCT Talent Acquisition Task Force. Transplant Cell Ther. 2024 06; 30(6):559-564.
    View in: PubMed
    Score: 0.006
  45. Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease. Nat Microbiol. 2024 Mar; 9(3):614-630.
    View in: PubMed
    Score: 0.006
  46. Immunobiology of acute graft-versus-host disease. Blood Rev. 2003 Dec; 17(4):187-94.
    View in: PubMed
    Score: 0.006
  47. Pathophysiology of acute graft-versus-host disease. Hematol Oncol. 2003 Dec; 21(4):149-61.
    View in: PubMed
    Score: 0.006
  48. Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline. J Clin Oncol. 2023 12 10; 41(35):5448-5472.
    View in: PubMed
    Score: 0.006
  49. Role of interleukin-18 in acute graft-vs-host disease. J Lab Clin Med. 2003 Jun; 141(6):365-71.
    View in: PubMed
    Score: 0.006
  50. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood. 2003 Apr 01; 101(7):2877-85.
    View in: PubMed
    Score: 0.005
  51. Colorectal cancer cells utilize autophagy to maintain mitochondrial metabolism for cell proliferation under nutrient stress. JCI Insight. 2021 06 17; 6(14).
    View in: PubMed
    Score: 0.005
  52. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transplant Cell Ther. 2021 06; 27(6):452-466.
    View in: PubMed
    Score: 0.005
  53. The Endoplasmic Reticulum Cargo Receptor SURF4 Facilitates Efficient Erythropoietin Secretion. Mol Cell Biol. 2020 Nov 06; 40(23).
    View in: PubMed
    Score: 0.005
  54. Prevention and Treatment of Acute Graft-versus-Host Disease in Children, Adolescents, and Young Adults. Biol Blood Marrow Transplant. 2020 05; 26(5):e101-e112.
    View in: PubMed
    Score: 0.004
  55. Computational analysis of continuous body temperature provides early discrimination of graft-versus-host disease in mice. Blood Adv. 2019 12 10; 3(23):3977-3981.
    View in: PubMed
    Score: 0.004
  56. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. Blood Adv. 2019 12 10; 3(23):4034-4042.
    View in: PubMed
    Score: 0.004
  57. MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells. Immunity. 2019 09 17; 51(3):479-490.e6.
    View in: PubMed
    Score: 0.004
  58. A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2019 08; 25(8):1492-1497.
    View in: PubMed
    Score: 0.004
  59. A Pipeline for Faecal Host DNA Analysis by Absolute Quantification of LINE-1 and Mitochondrial Genomic Elements Using ddPCR. Sci Rep. 2019 04 03; 9(1):5599.
    View in: PubMed
    Score: 0.004
  60. Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival. Bone Marrow Transplant. 2019 09; 54(9):1518-1520.
    View in: PubMed
    Score: 0.004
  61. Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2019 08; 25(8):1682-1688.
    View in: PubMed
    Score: 0.004
  62. SAG/RBX2 E3 Ubiquitin Ligase Differentially Regulates Inflammatory Responses of Myeloid Cell Subsets. Front Immunol. 2018; 9:2882.
    View in: PubMed
    Score: 0.004
  63. Survival signal REG3a prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease. J Clin Invest. 2018 11 01; 128(11):4970-4979.
    View in: PubMed
    Score: 0.004
  64. Cognitive Function and Quality of Life in Vorinostat-Treated Patients after Matched Unrelated Donor Myeloablative Conditioning Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 02; 25(2):343-353.
    View in: PubMed
    Score: 0.004
  65. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018 06 21; 131(25):2846-2855.
    View in: PubMed
    Score: 0.004
  66. The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biol Blood Marrow Transplant. 2018 07; 24(7):1322-1340.
    View in: PubMed
    Score: 0.004
  67. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018 03; 24(3):282-291.
    View in: PubMed
    Score: 0.004
  68. Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis. J Clin Invest. 2017 Jun 30; 127(7):2441-2451.
    View in: PubMed
    Score: 0.004
  69. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight. 2017 02 09; 2(3):e89798.
    View in: PubMed
    Score: 0.004
  70. Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Mar; 23(3):522-528.
    View in: PubMed
    Score: 0.004
  71. Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. Biol Blood Marrow Transplant. 2016 May; 22(5):862-8.
    View in: PubMed
    Score: 0.003
  72. Acute Graft-versus-Host Disease: Novel Biological Insights. Biol Blood Marrow Transplant. 2016 Jan; 22(1):11-6.
    View in: PubMed
    Score: 0.003
  73. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series. Biol Blood Marrow Transplant. 2016 Jan; 22(1):54-60.
    View in: PubMed
    Score: 0.003
  74. FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplant. 2016 Apr; 51(4):511-520.
    View in: PubMed
    Score: 0.003
  75. Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. Ann Hematol. 2015 Jun; 94(6):1033-41.
    View in: PubMed
    Score: 0.003
  76. Participation in clinical research: perspectives of adult patients and parents of pediatric patients undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1604-11.
    View in: PubMed
    Score: 0.003
  77. Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1407-17.
    View in: PubMed
    Score: 0.003
  78. Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1426-34.
    View in: PubMed
    Score: 0.003
  79. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013 Aug 08; 369(6):529-39.
    View in: PubMed
    Score: 0.003
  80. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)? Curr Stem Cell Res Ther. 2012 May; 7(3):229-39.
    View in: PubMed
    Score: 0.003
  81. TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes. Biol Blood Marrow Transplant. 2012 Oct; 18(10):1525-32.
    View in: PubMed
    Score: 0.003
  82. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood. 2012 Mar 22; 119(12):2960-3.
    View in: PubMed
    Score: 0.003
  83. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011 Dec 15; 118(25):6702-8.
    View in: PubMed
    Score: 0.002
  84. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood. 2011 Oct 13; 118(15):4258-64.
    View in: PubMed
    Score: 0.002
  85. Obesity was associated with inferior outcomes in simultaneous pancreas kidney transplant. Transplantation. 2010 May 15; 89(9):1117-25.
    View in: PubMed
    Score: 0.002
  86. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant. 2010 Jul; 16(7):907-14.
    View in: PubMed
    Score: 0.002
  87. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010 Jan 06; 2(13):13ra2.
    View in: PubMed
    Score: 0.002
  88. Emerging drugs for acute graft-versus-host disease. Expert Opin Emerg Drugs. 2009 Jun; 14(2):219-32.
    View in: PubMed
    Score: 0.002
  89. Graft-versus-host disease. Lancet. 2009 May 02; 373(9674):1550-61.
    View in: PubMed
    Score: 0.002
  90. A biomarker panel for acute graft-versus-host disease. Blood. 2009 Jan 08; 113(2):273-8.
    View in: PubMed
    Score: 0.002
  91. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. 2008 Feb 15; 111(4):2470-5.
    View in: PubMed
    Score: 0.002
  92. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005 Sep; 11(9):680-7.
    View in: PubMed
    Score: 0.002
  93. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003 Aug; 9(8):505-11.
    View in: PubMed
    Score: 0.001
  94. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. J Clin Invest. 2002 May; 109(9):1249-56.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.